Trial Profile
A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn's disease patients in sustained steroid-free remission on combination therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Azathioprine; Mercaptopurine; Methotrexate
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms SPARE
- 08 Aug 2022 Status changed from active, no longer recruiting to completed.
- 06 Jul 2021 Planned End Date changed from 1 Sep 2021 to 1 Oct 2021.
- 05 Mar 2020 Planned End Date changed from 1 Dec 2022 to 1 Sep 2021.